Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis
Gutierrez J, Ramirez G, Rundek T, Sacco RL
Archives of internal medicine · 141 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2012-06-25 · Arch Intern Med · vol. 172 · número 12 · págs. 909–19
- Editorial
- American Medical Association
- Citado
- 185 citas · más que el 100% de estudios similares · 25.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 80 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Acute Myocardial Infarction Research · Cancer, Lipids, and Metabolism
- Palabras clave
- statins, secondary prevention, recurrent cardiovascular events, sex differences, women, all-cause mortality, stroke, myocardial infarction, cardiovascular mortality, cholesterol-lowering therapy
- MeSH
- humans, cardiovascular diseases, hypercholesterolemia, hydroxymethylglutaryl-coa reductase inhibitors, sex factors, female, male, randomized controlled trials as topic, secondary prevention
4 autores
- José Gutierrez🇺🇸 · autor de correspondenciaColumbia University Irving Medical Center; Columbia University
- Gilbert Ramı́rez🇺🇸Florida International University
- Tatjana Rundek🇺🇸University of Miami; Florida International University; Columbia University
- Ralph L. Sacco🇺🇸University of Miami; Florida International University; Columbia University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The effect of statins on the prevention of cardiovascular events is well demonstrated. Whether this protective effect is equal for women and men remains less well established. Our objective was to evaluate if statin therapy is equally effective in decreasing recurrent cardiovascular events in women and men.
Data sources
Randomized clinical trials were searched in PubMed using as indexing terms (statins OR cholesterol lowering medications) AND (cardiovascular events OR stroke OR myocardial infarction OR cardiovascular death).
Study selection
We included randomized, double-blinded, placebo-controlled trials evaluating statins for secondary prevention of cardiovascular events. Studies with an open-label design and observational studies were excluded.
Data extraction
The earliest citation was used to determine the characteristic of the studied population and the methodology. All subsequent citations corresponding to the trial were evaluated for outcome rates by sex.
Data synthesis
Eleven trials representing 43,193 patients were included in the analysis. Overall, statin therapy was associated with a reduced risk of cardiovascular events in all outcomes for women (relative risk [RR], 0.81 [95% CI, 0.74-0.89]) and men (RR, 0.82 [95% CI, 0.78-0.85]). However, they did not reduce all-cause mortality in women vs men (RR, 0.92 [95% CI, 0.76-1.13] vs RR, 0.79 [95% CI, 0.720.87]) or stroke (RR, 0.92 [95% CI, 0.76-1.10] vs RR, 0.81 [95% CI, 0.72-0.92]).
Conclusions
Statin therapy is an effective intervention in the secondary prevention of cardiovascular events in both sexes, but there is no benefit on stroke and all-cause mortality in women.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.